| Allina Health Annandale Clinic | |
|
440 Elm St E Annandale MN 55302-1109 | |
| (320) 274-3744 | |
| (320) 274-8194 |
| Full Name | Allina Health Annandale Clinic |
|---|---|
| Speciality | Family Medicine |
| Location | 440 Elm St E, Annandale, Minnesota |
| Authorized Official Name and Position | Dominico Tallarico (COO) |
| Authorized Official Contact | 6122222222 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Allina Health Annandale Clinic Po Box 43 Mail Route 10860 Minneapolis MN 55440-0043 Ph: (612) 262-1166 | Allina Health Annandale Clinic 440 Elm St E Annandale MN 55302-1109 Ph: (320) 274-3744 |
| NPI Number | 1457657249 |
|---|---|
| Provider Enumeration Date | 01/27/2011 |
| Last Update Date | 03/21/2024 |
| Medicare PECOS PAC ID | 4587573613 |
|---|---|
| Medicare Enrollment ID | O20120221000258 |
News Archive
Usher syndrome (USH) is characterized by hearing loss or deafness at birth and progressive vision loss, and is the most common cause of inherited dual sensory deficit. No treatment is currently available to stop or slow the progression of vision or hearing loss in USH3, one of three clinical classifications for USH that are further divided into subtypes and all associated with different genes.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.
Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.
› Verified 9 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457657249 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| 261Q00000X | Clinic/center | (* (Not Available)) | Secondary |
News Archive
Usher syndrome (USH) is characterized by hearing loss or deafness at birth and progressive vision loss, and is the most common cause of inherited dual sensory deficit. No treatment is currently available to stop or slow the progression of vision or hearing loss in USH3, one of three clinical classifications for USH that are further divided into subtypes and all associated with different genes.
Celator Pharmaceuticals today announced that the first patient has been treated in a randomized Phase 2 clinical study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in patients with newly diagnosed acute myeloid leukemia (AML).
Researchers employ a structure-guided approach for the development of a series of ACE2-Fc variants using human IgG1 or IgG3 backbone.
Nuvilex, Inc., an emerging biotechnology provider of cell and gene therapy solutions through acquisition of SG Austria assets, realizes the important role for Cell-in-a-Box technology and aims to bring to light its use in the production of therapeutic antibodies for clinically important diseases.
› Verified 9 days ago
Above And Beyond Therapeutic Services Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 990 Elm St E, Annandale, MN 55302 Phone: 320-221-2674 |